DB:FZRQ

Stock Analysis Report

Executive Summary

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases.


Snowflake Analysis

Overvalued with weak fundamentals.


Similar Companies

Share Price & News

How has Immune Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FZRQ's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

FZRQ

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

-93.3%

FZRQ

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: FZRQ underperformed the German Biotechs industry which returned 3.7% over the past year.

Return vs Market: FZRQ underperformed the German Market which returned 6.1% over the past year.


Shareholder returns

FZRQIndustryMarket
7 Day0%-4.1%-5.7%
30 Day100.0%-8.2%-5.7%
90 Day-95.0%-2.0%-3.6%
1 Year-93.3%-93.3%4.0%3.7%9.3%6.1%
3 Yearn/a38.2%36.7%8.9%-0.7%
5 Year-100.0%-100.0%9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is Immune Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Immune Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

0.19x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate FZRQ's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate FZRQ's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: FZRQ is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: FZRQ is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FZRQ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FZRQ is good value based on its PB Ratio (0.2x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Immune Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immune Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Immune Pharmaceuticals performed over the past 5 years?

-30.4%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: FZRQ is currently unprofitable.

Growing Profit Margin: FZRQ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if FZRQ's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare FZRQ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FZRQ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: FZRQ has a negative Return on Equity (-1945.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Immune Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: FZRQ's short term assets ($364.0K) do not cover its short term liabilities ($14.9M).

Long Term Liabilities: FZRQ's short term assets ($364.0K) do not cover its long term liabilities ($5.0M).


Debt to Equity History and Analysis

Debt Level: FZRQ's debt to equity ratio (989.5%) is considered high.

Reducing Debt: FZRQ's debt to equity ratio has increased from 62.4% to 989.5% over the past 5 years.


Balance Sheet

Inventory Level: FZRQ has a low level of unsold assets or inventory.

Debt Coverage by Assets: FZRQ's debt is not covered by short term assets (assets are 0x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if FZRQ has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if FZRQ has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Immune Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate FZRQ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate FZRQ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FZRQ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FZRQ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FZRQ's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Gary Rabin (54yo)

1.1yrs

Tenure

0

Mr. Gary H. Rabin is Chief Executive Officer, President and Director of Immune Pharmaceuticals, Inc. since March 2019. He was Interim Chief Executive Officer of Immune Pharmaceuticals, Inc. in 2019. He has ...


Leadership Team

NamePositionTenureCompensationOwnership
John Clark
Controller & Principal Accounting Officer1.3yrsUS$176.08kno data
Gary Rabin
Interim CEO & Director1.1yrsno datano data
Christine Petraglia
Director of Investor Relations0yrsno datano data
Anna Baran-Djokovic
Director of Corporate Affairs0yrsno datano data
Miri Ben-Ami
President of Immune Oncology Pharmaceuticals Inc0yrsno datano data
Boris Shor
Executive Director of R&D & Scientific Partnerships4.4yrsno datano data
Ranch Kimball
Strategic Advisor3yrsno datano data

2.1yrs

Average Tenure

Experienced Management: FZRQ's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gary Rabin
Interim CEO & Director1.1yrsno datano data
William Sandborn
Member of Scientific Advisory Board0yrsno datano data
Brian Feagan
Member of Scientific Advisory Board0yrsno datano data
Neil Korman
Member of Scientific Advisory Board0yrsno datano data
Jean-Frédéric Colombel
Member of Scientific Advisory Board0yrsno datano data
John Neczesny
Independent Director4yrsUS$60.00kno data
Jeffrey Paley
Independent Director4yrsUS$60.00k0.00022% $1.4
Daniel Kazado
Director6.3yrsUS$40.00k0.031% $203.1
Pascal Joly
Member of Scientific Advisory Board0yrsno datano data
Vicky Werth
Member of Scientific Advisory Board0yrsno datano data

4.0yrs

Average Tenure

54yo

Average Age

Experienced Board: FZRQ's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: FZRQ insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 219.1%.


Top Shareholders

Company Information

Immune Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Immune Pharmaceuticals, Inc.
  • Ticker: FZRQ
  • Exchange: DB
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$700.296k
  • Listing Market Cap: US$645.183k
  • Shares outstanding: 181.90m
  • Website: https://www.immunepharma.com

Number of Employees


Location

  • Immune Pharmaceuticals, Inc.
  • 1 Bridge Plaza North
  • Suite 270
  • Fort Lee
  • New Jersey
  • 7024
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMNP.QOTCPK (Pink Sheets LLC)YesCommon StockUSUSDAug 2013
FZRQDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2013

Biography

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company’s lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company’s pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On February 17, 2019, Immune Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 22:24
End of Day Share Price2020/02/25 00:00
Earnings2018/09/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.